CJ thanks and after reading your post and the past few presentations by Dr Gray (one being with CEO Steve King) I believe we are about to witness one of the first BTDs that is 100% justified after reading the statistical significance that PS Targeting offers several other combos ..this one being anti-LAG 3+PS Targeting
12-8-16: Freimark/Hutchins Poster at Annual SanAntonio-Breast-Cancer-Symposium, “PS-Targeting Enhances Anti-LAG3 in Murine Breast Cancer Tumors”
Dec6-10 2016: “39th Annual San Antonio Breast Cancer Symposium” “...presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, AACR, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. As exciting strides are made in the field of breast cancer research & treatment, our program continues to present essential up-to-the minute info. combined with engrossing discussion for basic, translational, and clinical cancer research professionals. SABCS'16 is designed to provide state-of-the-art info. on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer & premalignant breast disease, to an intl. audience of academic, private physicians, and researchers. We anticipate 7,500 attendees from more than 90 countries.” http://www.sabcs.org https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-2 TRACK: Tumor Cell & Molecular Biology: Immunology & Preclin. Immunotherapy 12-8-16 7:30–9:00am Poster Session 2 #P2-04-12: “Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances the Activity of Immune Checkpoint Lag3 Targeting Antibodies in Murine Breast Tumors” - Gray MJ, Gong J, Jeff Hutchins, Bruce D. Freimark (Dir.Res/Preclin.Oncology) - Peregrine Pharmaceuticals
Market Data 
Markets 
AI
